GenoMethods is an English-language biotechnology media and intelligence publication focused on explaining how scientific methods develop into medical applications and commercial biotechnology. Our coverage connects the underlying biology and technology with the evidence, development decisions and market activity that shape the biotechnology sector.
Our editorial approach is methods-first and evidence-first. We aim to help readers understand not only what happened, but how a technology works, what evidence supports a claim, what remains uncertain, and what a development may mean scientifically, clinically and commercially. The goal is to provide enough context for readers to distinguish a meaningful development from a headline, promotional claim or preliminary signal.
What We Cover
GenoMethods focuses on biotechnology rather than general technology, general health or general finance. Our coverage is organized around connected scientific, clinical and commercial questions so readers can follow a development from its technical basis through its potential practical significance.
Methods and Platforms
We cover bioengineering, genome and cell engineering, synthetic biology, genomics, sequencing, bioinformatics, computational biology, scientific instrumentation and emerging experimental platforms.
Coverage may examine experimental design, benchmarking, validation, reproducibility, practical limitations and how a new method compares with existing approaches. A new technique is not treated as established simply because it is novel; the quality, scope and reproducibility of the supporting evidence remain important.
Medicine and Clinical Development
We cover drug discovery, translational biotechnology, clinical trials, gene therapy, cell therapy, genome editing, biomarkers, diagnostics and precision medicine.
We aim to distinguish early biological activity from established clinical benefit and to explain patient populations, endpoints, adverse events, follow-up, manufacturing and regulatory milestones where relevant. The stage of development and the limits of the available evidence are part of the story, not details to be omitted.
Companies and Markets
GenoMethods covers biotechnology companies, pipelines, licensing, strategic partnerships, financing, M&A, restructurings and other transactions when the underlying science or clinical assets are central to the story.
Market reporting should connect transaction economics with scientific and clinical evidence rather than treating biotechnology as generic financial news. Where relevant, we distinguish headline deal values from the specific economic terms that are actually disclosed.
Comparisons, Reviews and Rankings
GenoMethods may publish methodology-based comparisons, rankings, technology landscapes and data-driven lists related to biotechnology companies, platforms, tools and technologies when structured comparison helps readers understand meaningful differences between them.
Paid visibility does not determine editorial ranking position. Reviews and rankings are editorial products and should reflect the evidence, criteria and limitations relevant to the subject being evaluated.
How We Approach Biotechnology
Readers often encounter a scientific paper, clinical update or company announcement without enough context to understand what it actually means. A technically accurate announcement may still leave unanswered questions about validation, clinical relevance, limitations, competitive context or what evidence should come next.
GenoMethods tries to connect those layers rather than simply restating the original announcement. Our reporting commonly asks:
- What happened, and what materially changed?
- How does the method, platform or technology work?
- What evidence supports the central claim?
- What does the available evidence not yet prove?
- Why does the development matter scientifically?
- What could it mean for clinical development or medicine?
- What could it mean commercially or financially within biotechnology?
- What evidence, milestone or decision should readers watch next?
This approach can be summarized as: Biotechnology decoded from method to medicine to market.
Sources, Evidence and Independence
GenoMethods prefers primary and authoritative sources where reasonably possible. These may include scientific papers, clinical trial registries, regulatory documents, company filings, official disclosures, technical documentation, public datasets and scientific conference materials. The appropriate source depends on the type of claim being examined.
Company press releases may establish what a company has publicly stated, but they are not automatically treated as independent validation. Where a claim can be checked against research, regulatory records, clinical trial information or formal filings, those sources may provide stronger context.
GenoMethods currently displays third-party advertising through Google AdSense. Advertising relationships do not determine independent editorial conclusions, topic selection, corrections, reviews or ranking positions.
GenoMethods does not currently publish sponsored articles or use affiliate links as part of its standard publishing model.
Editorial History
- 2002
- GenoMethods was founded in 2002 with a focus on biotechnology and the methods used to understand, engineer and translate biological systems.
- Current editorial positioning
- The publication now organizes its biotechnology coverage around an evidence-first connection between method, medicine and market, linking technical developments to clinical and commercial context where that connection is meaningful.
Editorial Leadership
Adrian Cole is Founder & Editor-in-Chief, Bioengineering & Methods, with responsibility for GenoMethods editorial direction.
The current editorial structure also includes Elena MacLeod, Clinical Biotechnology Editor, and Vivian Lin, Biotech Markets & Transactions Editor. Together, these roles reflect the publication's Method → Medicine → Market framework.
Full editorial profiles are available at: team
Professional Information Disclaimer
GenoMethods content is informational. It does not provide personalized medical, legal, financial, tax, investment, mental health or other professional advice. Scientific, clinical and market reporting should be read as editorial information, not as individualized guidance for a reader's personal circumstances.
Contact
General: livelong@genomethods.org
Editorial: editorial@genomethods.org
Corrections: corrections@genomethods.org
More information: contact page
Related Pages
1 Broadway
Cambridge, MA 02142
United States